Marie Maugans Coleman
Psychiatric/Mental Health · Hutchinson, KSNPI 1730116070
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 457 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 457 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Vanda Pharmaceuticals Inc.$833
- Otsuka America Pharmaceutical, Inc.$783
- Lundbeck LLC$580
- Alkermes, Inc.$532
- plus $2K from 18 others
What the payments were for
- Food & beverage$7,802100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 67 | $1,373 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $1,272 |
| Vanda Pharmaceuticals Inc. | 41 | $833 |
| Otsuka America Pharmaceutical, Inc. | 55 | $783 |
| Lundbeck LLC | 40 | $580 |
| Alkermes, Inc. | 30 | $532 |
| Johnson & Johnson | 21 | $457 |
| Neurocrine Biosciences, Inc. | 26 | $457 |
| AbbVie | 16 | $267 |
| Sunovion Pharmaceuticals Inc. | 18 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $211 |
| Indivior Inc. | 15 | $209 |
| Eisai Inc. | 8 | $115 |
| Merck | 7 | $100 |
| Supernus Pharmaceuticals, Inc. | 5 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $76 |
| Corium, LLC | 2 | $50 |
| Ironshore Pharmaceuticals Inc. | 2 | $41 |
| Vertical Pharmaceuticals, LLC | 2 | $29 |
| Amgen | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Avanir Pharmaceuticals, Inc. | 2 | $23 |
| Noven Therapeutics, LLC | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$131
- INVEGA SUSTENNA$119
- CAPLYTA$110
How this compares
$7,802 in reported general payments places this provider in the 90th percentile of 404 psychiatric/mental health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 119 | $197,886 |
| VraylarCariprazine Hcl | 116 | $170,576 |
| AustedoDeutetrabenazine | 13 | $65,963 |
| TrintellixVortioxetine Hydrobromide | 86 | $50,459 |
| Abilify MaintenaAripiprazole | 18 | $47,623 |
| Invega SustennaPaliperidone Palmitate | 11 | $36,679 |
| CaplytaLumateperone Tosylate | 16 | $29,478 |
| Lurasidone Hcl | 47 | $18,130 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $18,020 |
| Asenapine Maleate | 24 | $8,864 |
| Quillivant XrMethylphenidate Hcl | 12 | $7,616 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 58 | $6,695 |
| Atomoxetine Hcl | 80 | $6,459 |
| Paliperidone ErPaliperidone | 56 | $5,830 |
| Aripiprazole | 185 | $5,243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $783 | $245,508137 claims |
| AbbVieVraylar | $267 | $170,576116 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,373 | $65,96313 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $211 | $50,45986 claims |
| Johnson & JohnsonInvega Sustenna | $457 | $36,67911 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,272 | $29,47816 claims |
| Alkermes, Inc.Lybalvi | $532 | $18,02011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Hutchinson
- Belinda BagbyHutchinson$39K
- Susan RuleHutchinson$6K
- Tina NortonHutchinson$4K
- Eric ThomasonPittsburg$333K
- Hayley KnappWichita$31K
- Jennifer KubinBaldwin City$26K
- Uyen DinhPittsburg$20K
- Louise MuhoziKansas City$14K
- Theresa MuellerOverland Park$14K
- Shiney ZchariaOlathe$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.